Search

Search Constraints

You searched for: Author/Creator Millenson, Michael

Search Results

1. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non‐Hodgkin lymphoma: a multicentre phase II study. (25th April 2014)

2. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Issue 10 (October 2013)

3. Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Issue 7 (9th December 2014)

4. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab. Issue 20 (6th August 2013)

5. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project. Issue 20 (6th August 2013)

6. Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. (20th September 2013)

7. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Issue 4 (April 2018)

8. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Issue 4 (April 2018)